Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Adverse event

From: Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer

 

IO + ChT (n = 82)

ChT (n = 53)

Chi-square test

Adverse event

Any grade

%

Grade ≥ 3

%

Any grade

%

Grade ≥ 3

%

P (Any grade)

P (Grade ≥ 3)

Treatment related

          

Decreased leukocyte count

56

68.20

16

19.51

33

62.26

6

11.32

.470

.678

Decreased neutrophil count

55

67.07

30

36.59

38

71.70

17

32.08

.571

.776

Decreased red blood cell count

76

92.68

6

7.31

42

79.25

2

3.77

.022

.537

Decreased platelet count

36

43.90

9

10.96

22

41.51

4

7.55

.784

.488

Decreased lymphocyte count

65

79.27

18

21.95

38

71.70

12

22.64

.312

.765

Transaminase increase

1

1.22

0

0

4

7.55

0

0

.057

/

Creatinine increase

2

2.44

0

0

1

1.89

0

0

.832

/

Nausea or vomiting

44

53.66

0

0

40

75.47

0

0

.011

/

Diarrhea

2

2.44

0

0

6

11.32

0

0

.033

/

Constipation

31

37.80

0

0

25

47.17

0

0

.281

/

  1. Abbreviations: IO, immunotherapy; ChT, chemotherapy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us